The Immune Response Corporation Report issue

For profit Phase 2 Phase 3
Founded: Carlsbad CA United States (1986)
Status: Defunct (2009)

Organization Overview

First Clinical Trial
1999
NCT00002172
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Immune Response BioPharma | Immune Response BioPharma, Inc. | Immune Response BioPharma, Inc. Chief R&D Officer

Active Ingredients

Drugs in Phase 3 Trials (4)

hiv-1 immunogen (4 trials)

incomplete freund's adjuvant (3 trials)

ir103 (1 trial)

neurovax (3 trials)

Drugs in Phase 2 Trials (1)

remune (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Communicable Diseases (Phase 3)

HIV Infections (Phase 3)

Infections (Phase 3)

Multiple Sclerosis (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 5